One study, published in Surgical Innovation, showed that of 110 GERD patients who underwent TIF, typically and atypical symptom scores were normalized in 75-80 percent of patients. Proton pump inhibitors were discontinued in 93 percent of patients. In all, 20 percent of patient reported having improved symptomatically, whereas only 8 percent had ongoing GERD.
In another study, published in Surgical Endoscopy, researchers conducted follow-up with 37 patients who underwent TIF after six months. Results from their procedures showed significant improvements in both typical and atypical symptoms in 64 percent and 70-80 percent of patients, respectively. Also 82 percent of patients stopped their reflux medications.
A study published in Surgery also supported the utilization of TIF in GERD patients. The study’s results showed that out of 26 patients, 79 percent no longer needed their reflux medications 6-7 weeks after their procedure.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
